Independent validation of LIPA as a molecular target in TNBC

Dallas, TX. October 2, 2023: Etira is pleased to note the independent validation of LIPA as a molecular target in TNBC in a preprint in biorxiv from Dr. Esser’s group in Dusseldorf, Germany.

The authors conclude that LIPA-activity is a novel pharmacological target in TNBC therapy and argue for the implementation of LIPA inhibitors into personalized treatment in the future. These findings support our approach with drugs like ERX-41 and ERX-315 that target LIPA. Our phase I clinical trial with ERX-315 is scheduled to begin in Q2 2024.

https://www.biorxiv.org/content/10.1101/2023.10.01.560038v1

ERX-41 and ERX-315 are investigational medicine and have not been approved for any use. Safety and efficacy have not been established.